-
Scandic Trust Group strengthens sales network with First Idea Consultant
-
France urges EU to sanction Shein platform
-
France opt for Le Garrec as Dupont replacement for South Africa Test
-
Turmoil in tiaras at Miss Universe pageant in Thailand
-
Probe into Thales defence group looking at Indonesian contract
-
US to cancel flights as longest govt shutdown drags on
-
Home in Nigeria, ex-refugees find themselves in a war zone
-
Doncic's Lakers hold off Wembanyama's Spurs, Blazers silence Thunder
-
For Turkey's LGBTQ community, draft law sparks existential alarm
-
Musk's $1 trillion pay package to face Tesla shareholder vote
-
Tonga rugby league star out of intensive care after seizure
-
Argentine ex-president Kirchner goes on trial in new corruption case
-
Dams, housing, pensions: Franco disinformation flourishes online
-
Endo returns as Japan look to build on Brazil win
-
Franco captivates young Spaniards 50 years after death
-
German steel industry girds for uncertain future
-
IPL champions Bengaluru could be sold for 'as much as $2 billion'
-
Budget impasse threatens Belgium's ruling coalition
-
New Zealand ex-top cop admits to having material showing child abuse, bestiality
-
BoE set for finely balanced pre-budget rate call
-
Australian kingpin obtains shorter sentence over drug charge
-
Weatherald's unenviable Ashes task: fill giant hole at top left by Warner
-
Ovechkin first to score 900 NHL goals as Capitals beat Blues
-
On Mexico City's streets, vendors fight to make it to World Cup
-
Asian markets bounce from selloff as US jobs beat forecasts
-
Philippine death toll tops 140 as typhoon heads towards Vietnam
-
Kyrgios targets 'miracle' Australian Open return after knee improves
-
'AI president': Trump deepfakes glorify himself, trash rivals
-
Belgium probes drone sightings after flights halted overnight
-
Five things to know about 'forest COP' host city Belem
-
World leaders to rally climate fight ahead of Amazon summit
-
Engine fell off US cargo plane before deadly crash: officials
-
Mexican leader calls for tougher sexual harassment laws after attack
-
Meghan Markle set for big screen return: reports
-
Japan deploys troops after wave of deadly bear attacks
-
FIFA announce new peace prize to be awarded at World Cup draw in Washington
-
Australia's Cummins hints at return for second Ashes Test
-
Boeing settles with one plaintiff in 737 MAX crash trial
-
Man City win as Inter stay perfect, Barca held in Champions League
-
French superstar DJ Snake wants new album to 'build bridges'
-
Barca rescue draw at Club Brugge in six-goal thriller
-
Foden hits top form as Man City thrash Dortmund
-
NBA officials brief Congress committee over gambling probe
-
Inter beat Kairat Almaty to maintain Champions League perfection
-
Newcastle sink Bilbao to extend Champions League winning run
-
Wall Street stocks rebound after positive jobs data
-
LPGA, European tour partner with Saudis for new Vegas event
-
Eyes turn to space to feed power-hungry data centers
-
Jazz lose Kessler for season with shoulder injury
-
League scoring leader Messi among MLS Best XI squad
Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.
The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.
His next quests include, among others, developing a vaccine against all future coronaviruses.
"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.
"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."
- Twin breakthroughs-
The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.
But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.
"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.
In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.
"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.
"We sat there staring at our phones for five years, and they never rang!"
With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."
Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.
- Helping people -
Weissman grew up in Lexington, Massachusetts.
His father and mother, both since retired, were an engineer and dental hygienist, respectively.
"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.
He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.
As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.
Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.
"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.
Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.
Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.
Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.
Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.
S.Gantenbein--VB